{"title":"Navigating Chronic Pain in Patients with Cirrhosis: Unique Analgesic Considerations and Non-Pharmacologic Options.","authors":"Lisa X Deng, Jessica B Rubin","doi":"10.1007/s11901-026-00735-9","DOIUrl":"10.1007/s11901-026-00735-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic pain affects 40-80% of patients with chronic liver disease, yet management remains challenging due to impaired drug metabolism, limited evidence, and the absence of disease-specific guidelines. This review summarizes the evidence for pharmacologic and non-pharmacologic pain management strategies in patients with cirrhosis.</p><p><strong>Recent findings: </strong>Nearly every analgesic class carries risk in patients with cirrhosis, and most prescribing recommendations are based on pharmacokinetic data and expert opinion rather than clinical trials. Opioid prescribing has declined in recent years, but nonopioid alternatives have not increased proportionally. Non-pharmacologic modalities have been scarcely studied in this population. Shared comorbidities and risk factors, including alcohol use, metabolic disease, sleep disturbances, and psychiatric conditions, represent modifiable therapeutic targets that may improve pain while altering liver disease trajectory.</p><p><strong>Summary: </strong>Pain management in patients with cirrhosis requires an individualized, multimodal approach integrating pharmacologic therapy, non-pharmacologic interventions, and comorbidity management. Further research, including both well-designed observational studies and prospective trials, is needed to generate evidence-based guidance for this underserved population.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"25 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatocellular Carcinoma in Africa: Epidemiology, Prevention and Outcomes.","authors":"Joseph A Akambase, Ponsiano Ocama, Jose D Debes","doi":"10.1007/s11901-026-00744-8","DOIUrl":"10.1007/s11901-026-00744-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review synthesizes the current knowledge of hepatocellular carcinoma (HCC) epidemiology across Northern and sub-Saharan Africa. We examine how causes of HCC differ by region, highlight prevention and early detection strategies, and identify gaps in treatment and palliative care to improve outcomes.</p><p><strong>Recent findings: </strong>The causes of HCC vary markedly across the continent. HCV predominates in Northern Africa, whereas HBV infection and dietary aflatoxin exposure prevail in sub-Saharan Africa. Rising obesity, diabetes, harmful alcohol use, and hepatitis D co-infection are important but under-researched contributors. Most patients still present with advanced disease, fewer than 6% receive curative therapy, median survival is measured in months, and access to palliative care remains dismal.</p><p><strong>Summary: </strong>HCC poses a major challenge in Africa, marked by high incidence, early age at diagnosis, and among the worst survival outcomes worldwide. Primary prevention through HBV birth-dose vaccination, aflatoxin mitigation, and population-level HCV treatment offers the most effective way to reduce mortality, yet implementation barriers persist.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"25 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13372829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sajid Jalil, Mangesh Pagadala, Nicholas Dunn, Hanna Blaney, Mohamed Elfeki, Nimish Thakral, Ashwani K Singal
{"title":"Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.","authors":"Sajid Jalil, Mangesh Pagadala, Nicholas Dunn, Hanna Blaney, Mohamed Elfeki, Nimish Thakral, Ashwani K Singal","doi":"10.1007/s11901-025-00713-7","DOIUrl":"10.1007/s11901-025-00713-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Vibration-controlled transient elastography (VCTE) has become a cornerstone in the noninvasive assessment of liver disease across etiologies. This review highlights its role in risk stratification and longitudinal monitoring, emphasizing its value in both clinical practice and research settings, including community and academic hepatology.</p><p><strong>Recent findings: </strong>VCTE reliably assesses liver fibrosis severity and clinically significant portal hypertension and enables ongoing monitoring of therapeutic response. It also predicts liver-related events and mortality. Recognizing its limitations and potential confounders is essential to ensure diagnostic accuracy, and its performance can be further enhanced by integrating clinical and biochemical variables.</p><p><strong>Summary: </strong>Despite inherent limitations, improvements in probe design, standardized protocols, and composite algorithms have expanded its clinical utility. The 2022 Baveno consensus established clear guidance for using VCTE to identify clinically significant portal hypertension, ultimately aiming to prevent first decompensation and improve patient outcomes.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12781356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdellatif Ismail, Mohanad Awadalla, Suvisesh Pothuraju, Ashwani K Singal
{"title":"Hepatic Hydrothorax: A Review.","authors":"Abdellatif Ismail, Mohanad Awadalla, Suvisesh Pothuraju, Ashwani K Singal","doi":"10.1007/s11901-025-00677-8","DOIUrl":"10.1007/s11901-025-00677-8","url":null,"abstract":"<p><strong>Purpose of the review: </strong>To review epidemiology, pathogenesis, diagnosis, and management of hepatic hydrothorax.</p><p><strong>Recent findings: </strong>Refractory hepatic hydrothorax is an independent predictor of mortality in patients with decompensated cirrhosis. Allocation of Model for End-Stage Liver Disease exception points for patients with refractory hydrothorax was found to be associated with a significant reduction in post liver transplant mortality.</p><p><strong>Summary: </strong>Hepatic hydrothorax, pleural effusion in patients with decompensated liver cirrhosis without primary pleural and cardiopulmonary pathology is associated with a high rate of morbidity and mortality. Pathogenesis is a combination of salt and water retention and unidirectional movement of fluid from the peritoneal to the thoracic cavity. Diagnosis relies on pleural fluid analysis and ruling out a primary pleural and cardiopulmonary pathology. Management is complex and requires a stepwise and multidisciplinary approach. All patients with refractory hydrothorax should be evaluated for liver transplant.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatima Elmustafa, Mahima Tyagi, Harpreet Kaur, Hanna Blaney, Chencheng Xie, Sajid Jalil, Ashwani K Singal
{"title":"Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?","authors":"Fatima Elmustafa, Mahima Tyagi, Harpreet Kaur, Hanna Blaney, Chencheng Xie, Sajid Jalil, Ashwani K Singal","doi":"10.1007/s11901-025-00712-8","DOIUrl":"10.1007/s11901-025-00712-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>The new nomenclature of steatotic liver disease overcame the stigma associated with non-alcohol fatty liver disease term changing to metabolic dysfunction associated steatototic liver disease (MASLD), and introduced a new entity of metabolic dysfunction and alcohol associated liver disease or Met-ALD. Introducing MetALD as a distinct clinical entity is challenging in clinical practice, but at the same time brings in opportunities for research to understand the various aspects of risk stratification, prognosis and natural history, pharmacological management, and designing clinical trials. This article delves into all these aspects of Met-ALD.</p><p><strong>Recent findings: </strong>This overview provides new insights in the disease and pathogenesis of liver injury with interaction and pathways driven by both the risk factors of cardiometabolic risk factors and of alcohol use in patients with Met-ALD.</p><p><strong>Summary: </strong>MetALD is a distinct form of steatotic liver disease with phenotype overlapping both MASLD and alcohol associated liver disease (ALD). It addresses a key clinical reality that <b>metabolic dysfunction and alcohol consumption frequently coexist</b> and synergistically worsen liver injury. By filling a major gap in current classifications, MetALD promotes accurate patient stratification, improved screening for dual risk factors, and tailored therapeutic strategies. Its recognition also has significant implications for clinical trials, epidemiologic research, and public health, given the global rise in obesity and persistent alcohol use.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pre-Operative Assessment of Patients with Cirrhosis for Extrahepatic Surgery.","authors":"Claire Durkin, Nadim Mahmud","doi":"10.1007/s11901-025-00697-4","DOIUrl":"10.1007/s11901-025-00697-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Patients with cirrhosis are at increased risk of peri-operative morbidity and mortality compared to those without cirrhosis, requiring careful pre-operative assessment of their liver disease, extra-hepatic comorbidities, and surgery-specific risk factors.</p><p><strong>Recent findings: </strong>Adverse surgical outcomes in this population are often related to complications of advanced liver disease, including portal hypertension, impaired hemostasis, malnutrition/sarcopenia, and infection. Risk prediction tools, including the Child-Turcotte-Pugh score, Model for End-Stage Liver Disease score, Mayo Risk Score, and VOCAL-Penn Score, can be used to estimate post-operative mortality and support clinical decision-making when assessing surgical candidacy. Several common procedures, including hernia repair, laparoscopic cholecystectomy, and sleeve gastrectomy, are well-tolerated in appropriate candidates. Pre-procedural transplant evaluation and referral to a high-volume cirrhosis surgery center should be considered when feasible.</p><p><strong>Summary: </strong>This review discusses the pathophysiological mechanisms underlying increased peri-operative risk in cirrhosis, the application of surgical risk scores, liver-related contraindications to surgery, and specific considerations for several common procedures.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"24 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials.","authors":"Jing Ma, Hui Gao, Ge Zeng, Nazmul Huda, Yanchao Jiang, Themis Thoudam, Zhihong Yang, Suthat Liangpunsakul","doi":"10.1007/s11901-025-00703-9","DOIUrl":"10.1007/s11901-025-00703-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Alcohol-associated hepatitis (AH) is a severe manifestation of alcohol-associated liver disease with high short-term mortality and limited treatment options. This review synthesizes mechanistic insights into AH pathogenesis and evaluates both failed and emerging clinical trials to guide targeted therapeutic development.</p><p><strong>Recent findings: </strong>AH arises from intertwined mechanisms including hepatotoxicity, oxidative stress, inflammation, impaired regeneration, and gut-liver axis disruption. Trials targeting inflammatory cytokines or apoptosis pathways have not demonstrated survival benefit and raised safety concerns. Current investigations emphasize therapies that mitigate oxidative stress, enhance hepatocyte regeneration, and restore gut-liver integrity. Novel agents such as interleukin-22 (IL-22), granulocyte colony-stimulating factor (G-CSF), probiotics, fecal microbiota transplantation (FMT), larsucosterol, and farnesoid X receptor (FXR) agonists are under evaluation.</p><p><strong>Summary: </strong>Although no effective pharmacologic therapy is yet available, advances in understanding AH biology provide a framework for mechanism-based strategies. Integrating hepatology with addiction medicine and incorporating stratified trial designs will be essential to advance effective therapies.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"24 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12559046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"AIH Therapy: Beyond First‑Line.","authors":"Irina Adao, Arielle Klepper, Michele Tana","doi":"10.1007/s11901-024-00657-4","DOIUrl":"10.1007/s11901-024-00657-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon.</p><p><strong>Recent findings: </strong>Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color.</p><p><strong>Summary: </strong>While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies.</p>","PeriodicalId":520883,"journal":{"name":"Current hepatology reports","volume":"23 3","pages":"341-348"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12830046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}